FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2913361073> ?p ?o ?g. }

• W2913361073 endingPage "4406" @default.
• W2913361073 startingPage "4406" @default.
• W2913361073 abstract "Abstract Introduction: CD39/CD73/ADO/A2A system plays important roles in tumor growth and therapy. Extracellular adenosine (ADO) receptor A2A (A2AR) is the dominant receptor expressed on chronic lymphocytic leukemia (CLL) cells. ADO has been shown to protect CLL cells from spontaneous and drug-induced apoptosis through A2AR activation. Overexpression of hypoxia inducible factor-1α (HIF-1α), an important mediator controlling the expression of a wide variety of apoptotic genes, has been observed in bone marrow leukemic cells from CLL patients. However, the reciprocal action of A2AR and HIF-1α in CLL remains elusive. This study was aimed to explore the molecular mechanisms underlying the relationship between A2AR activation and HIF-1α in CLL. Materials and Methods: Peripheral blood (PB) and bone marrow (BM) samples were collected from 30 healthy volunteers (control) and 20 patients who were diagnosed with CLL for the first time at the Hematology Department in our hospital. CD39/CD73/ADO/A2AR axis-related protein and HIF-1α protein expressions in CLL PB and BM tissues were examined by Western-blot. CD39, CD73, A2AR and HIF-1α expression on CLL cells were also determined by FACS. CLL cell line (Lym-2) was purchased from ATCC and incubated in DMEM medium supplemented with 10% FBS. The protein expressions of CD39, CD73 and A2AR on Lym-2 cells were confirmed by Western-blot. To study the impacts of A2AR activation and inactivation on CLL cells, CLL cells were treated with A2AR agonist CGS21680 or antagonist SCH58261, followed by determination of cell proliferation and HIF-1α protein expression. Results: The protein expressions of CD39, CD73, A2AR and HIF-1α were higher in CLL group than those in control group (BM: CD39 1.471 vs 0.926, CD73 1.097 vs 0.489, A2AR 1.139 vs 0.342 and HIF-1α 0.940 vs 0.362, P<0.05 Figure 1A; PB : CD39 1.809 vs 1.331, CD73 1.039 vs 0.653, A2AR 1.738 vs 1.119 and HIF-1α 1.336 vs 1.010, P<0.05 Figure 1B). Moreover, CD73 and HIF-1α protein expression was found to have relationship with disease stage. Patients who belonged to stage IV (Rai) and stage B/C (Binet) exhibited higher levels of CD73 and HIF-1α than patients who belonged to stage I to III (Rai) and stage A (Binet) . Data from FACS analysis showed that the proportion of CD39+CLL cells was higher than CD73+CLL cells and HIF-1α+CLL cells (P<0.05, Figure 2A). When compared to control group, the proportions of CD39+cells and CD73+ cells were significant higher in CLL group (Figure 2B). Western-blot results showed that Lym-2 cells expressed CD39, CD73 and A2AR simultaneously (Figure 3A). The results from CLL cells and A2AR agonist/antagonist incubation showed that when CGS21680 concentration was of ≥ 10uM, cell proliferation was promoted obviously (Figure 3B). On the contrary, SCH58261 could inhibit CLL cells proliferation when its concentration was of ≥5uM at a concentration dependent manner (Figure 3C). Moreover, HIF-1α protein expression was also affected by A2AR agonist at a concentration dependent manner(0uM 0.851, 10uM 1.116, 20uM 1.420, 50uM 1.41, Figure 3D). Conclusion: Our study showed that ADO produced by CD39 and CD73 could affect CLL cells proliferation and HIF-1α expression through A2AR-mediated mechanisms. The exploration of the molecular mechanisms underlying the relationship between A2AR activation and HIF-1α could help us to find a novel approach to CLL therapy. Disclosures: No relevant conflicts of interest to declare. Disclosures No relevant conflicts of interest to declare." @default.
• W2913361073 created "2019-02-21" @default.
• W2913361073 creator A5006822602 @default.
• W2913361073 creator A5046225712 @default.
• W2913361073 creator A5081844561 @default.
• W2913361073 creator A5082692871 @default.
• W2913361073 creator A5087384383 @default.
• W2913361073 date "2018-11-29" @default.
• W2913361073 modified "2023-09-30" @default.
• W2913361073 title "The Role of CD39/CD73/Ado/A2AR Axis and HIF-1α in Chronic Lymphocytic Leukemia" @default.
• W2913361073 doi "https://doi.org/10.1182/blood-2018-99-115732" @default.
• W2913361073 hasPublicationYear "2018" @default.
• W2913361073 type Work @default.
• W2913361073 sameAs 2913361073 @default.
• W2913361073 citedByCount "4" @default.
• W2913361073 countsByYear W29133610732020 @default.
• W2913361073 countsByYear W29133610732022 @default.
• W2913361073 countsByYear W29133610732023 @default.
• W2913361073 crossrefType "journal-article" @default.
• W2913361073 hasAuthorship W2913361073A5006822602 @default.
• W2913361073 hasAuthorship W2913361073A5046225712 @default.
• W2913361073 hasAuthorship W2913361073A5081844561 @default.
• W2913361073 hasAuthorship W2913361073A5082692871 @default.
• W2913361073 hasAuthorship W2913361073A5087384383 @default.
• W2913361073 hasConcept C126322002 @default.
• W2913361073 hasConcept C170493617 @default.
• W2913361073 hasConcept C185592680 @default.
• W2913361073 hasConcept C190283241 @default.
• W2913361073 hasConcept C194409129 @default.
• W2913361073 hasConcept C203014093 @default.
• W2913361073 hasConcept C2776694085 @default.
• W2913361073 hasConcept C2776755627 @default.
• W2913361073 hasConcept C2777938653 @default.
• W2913361073 hasConcept C2778461978 @default.
• W2913361073 hasConcept C2778491162 @default.
• W2913361073 hasConcept C2778938600 @default.
• W2913361073 hasConcept C2779263901 @default.
• W2913361073 hasConcept C2780007613 @default.
• W2913361073 hasConcept C502942594 @default.
• W2913361073 hasConcept C55493867 @default.
• W2913361073 hasConcept C67907053 @default.
• W2913361073 hasConcept C71924100 @default.
• W2913361073 hasConcept C86803240 @default.
• W2913361073 hasConceptScore W2913361073C126322002 @default.
• W2913361073 hasConceptScore W2913361073C170493617 @default.
• W2913361073 hasConceptScore W2913361073C185592680 @default.
• W2913361073 hasConceptScore W2913361073C190283241 @default.
• W2913361073 hasConceptScore W2913361073C194409129 @default.
• W2913361073 hasConceptScore W2913361073C203014093 @default.
• W2913361073 hasConceptScore W2913361073C2776694085 @default.
• W2913361073 hasConceptScore W2913361073C2776755627 @default.
• W2913361073 hasConceptScore W2913361073C2777938653 @default.
• W2913361073 hasConceptScore W2913361073C2778461978 @default.
• W2913361073 hasConceptScore W2913361073C2778491162 @default.
• W2913361073 hasConceptScore W2913361073C2778938600 @default.
• W2913361073 hasConceptScore W2913361073C2779263901 @default.
• W2913361073 hasConceptScore W2913361073C2780007613 @default.
• W2913361073 hasConceptScore W2913361073C502942594 @default.
• W2913361073 hasConceptScore W2913361073C55493867 @default.
• W2913361073 hasConceptScore W2913361073C67907053 @default.
• W2913361073 hasConceptScore W2913361073C71924100 @default.
• W2913361073 hasConceptScore W2913361073C86803240 @default.
• W2913361073 hasIssue "Supplement 1" @default.
• W2913361073 hasLocation W29133610731 @default.
• W2913361073 hasOpenAccess W2913361073 @default.
• W2913361073 hasPrimaryLocation W29133610731 @default.
• W2913361073 hasRelatedWork W1826292038 @default.
• W2913361073 hasRelatedWork W1973709544 @default.
• W2913361073 hasRelatedWork W1994460484 @default.
• W2913361073 hasRelatedWork W2015045838 @default.
• W2913361073 hasRelatedWork W2017727545 @default.
• W2913361073 hasRelatedWork W2033084703 @default.
• W2913361073 hasRelatedWork W2063351090 @default.
• W2913361073 hasRelatedWork W2073929083 @default.
• W2913361073 hasRelatedWork W2883739273 @default.
• W2913361073 hasRelatedWork W50612664 @default.
• W2913361073 hasVolume "132" @default.
• W2913361073 isParatext "false" @default.
• W2913361073 isRetracted "false" @default.
• W2913361073 magId "2913361073" @default.
• W2913361073 workType "article" @default.